Yujin Hoshida

This study identifies CLSTN3B as a driver of MASLD by promoting LD biogenesis and altering lipid partitioning between LDs and mitochondria, leading to mitochondrial dysfunction and oxidative stress.

This study shows that CLSTN3B promotes lipid droplet maturation in hepatocytes and that its deletion reduces steatohepatitis in mice, with a positive correlation between CLSTN3B expression and MASLD severity in humans.

This paper develops a molecular trajectory-based framework to model MASLD progression using transcriptomic and proteomic data, identifying novel biomarkers and mechanistic insights.

The paper uses whole-genome sequencing to predict cell-of-origin for primary liver cancers, finding heterogeneity in origin predictions across cancer types.

MS.liverK is an R package that implements tools for computing molecular subtypes and functional signatures in liver cancer using transcriptome data.